Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 December 2019
 
Share
News 13/12/2019
Five new medicines recommended for approval
EMA’s human medicines committee () recommended five medicines for approval at its December 2019 meeting.
The Committee recommended granting a  for Beovu (brolucizumab) for the treatment of neovascular (‘wet’) age-related macular degeneration, a disease that affects the central part of the retina at the back of the eye and causes loss of ‘straight-ahead’ vision.
The  adopted a positive opinion for Recarbrio (imipenem / cilastatin / relebactam), for the treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options.
The  Amsparity (adalimumab) received a positive opinion for the treatment of certain inflammatory and autoimmune disorders.
The  recommended granting  for two : Azacitidine Accord(azacitidine), for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia, diseases in which the body produces large numbers of abnormal blood cells; and Dexmedetomidine Accord (dexmedetomidine), for the induction of light to moderate sedation of adults in an intensive care unit.
Eight recommendations on extensions of therapeutic indication
The Committee recommended extensions of  for Akynzeo, Cyramza, Darzalex, Dificlir, Erleada, Sirturo, Stelara and Vyndaqel.
Agenda and minutes
The agenda of the December meeting is published on EMA's website. Minutes of the November 2019 

CHMPmeeting will be published in the coming weeks.
CHMP statistics
Key figures from the December 2019  meeting are represented in the graphic below.
